| (Values in U.S. Thousands) | Dec, 2015 | Dec, 2014 | Dec, 2013 | Dec, 2012 | Dec, 2011 |
| Sales | 0 | 0 | 0 | 0 | 150 |
| Sales Growth | unch | unch | unch | -100.00% | +650.01% |
| Net Income | -32,580 | -49,960 | -38,760 | -3,420 | -42,660 |
| Net Income Growth | +34.79% | -28.90% | -1,033.33% | +91.98% | -173.11% |
Oncothyreon Inc (ONTY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Oncothyreon Inc., formerly Biomira Inc. is a clinical-stage biopharmaceutical company focused primarily on the development and commercialization of therapeutic products for the treatment of cancer. The company is currently developing multiple therapeutic candidates designed to target cancer in specific and effective ways. Headquartered in Seattle, Washington, the primary goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. The Company's lead product candidate is Stimuvax, which is a cancer vaccine in Phase III development for non-small cell lung cancer. Oncothyreon has an exclusive, worldwide collaboration agreement with Merck KGaA of Darmstadt, Germany, for the development and commercialization of Stimuvax. Its pipeline of clinical and preclinical-stage small molecule product candidates includes PX-12, PX-478 and PX-866, from ProlX Pharmaceuticals Corporation.